Heartburn is common, but persistent chest discomfort or difficulty swallowing could signal serious issues. Gastroesophageal ...

Phathom Pharmaceuticals (PHAT) is a good biotech to keep an eye on in the coming months because it is gearing up to potentially receive an expanded FDA approval of its drug Voquenza as a daily ...

This retrospective study shows that among nearly 160,000 patients with pulmonary hypertension (PH), those who also had gastroesophageal reflux disease (GERD) had lower rates of morbidity and mortality ...

DEAR MAYO CLINIC: I saw a story on the news about magnets being used to treat patients with GERD. Is this treatment safe? How does it work? I’ve taken prescription drugs for GERD for years and would ...

telemedicine Researchers examined the risks for pneumonia and exacerbation of COPD after PPI treatment for GERD. The risk for symptom exacerbation reduced after PPI treatment for patients with GERD ...

Please provide your email address to receive an email when new articles are posted on . Proton pump inhibitors with histamine 2 receptor antagonists reduced all-cause mortality in patients with ...

The FDA approved vonoprazan (Voquezna) as a daily treatment for heartburn associated with non-erosive gastroesophageal reflux disease (GERD) in adults. GERD is a condition in which acidic stomach ...

International Foundation for Gastrointestinal Disorders (IFFGD) launches #LetsTalkGERD, a social campaign raising awareness about Gastroesophageal Reflux Disease (GERD).

Phathom Pharmaceuticals launched its first broadcast direct-to-consumer (DTC) campaign to promote Voquezna, its treatment for all severities of erosive gastroesophageal reflux disease (GERD), ...

NORWALK, Conn., Oct. 24, 2017 /CNW/ -- Mederi Therapeutics Inc. has announced new data on Stretta Therapy presented at the 2017 American College of Gastroenterology Congress (ACG2017). Authored by Dr.

The Linx device is a small ring of magnetic beads designed to treat gastroesophageal reflux disease by constricting the ...

Last month, the Food and Drug Administration (FDA) approved Voquenza Dual (vonoprazan fumarate + amoxicillin) and Triple Paks (vonoprazan fumarate + amoxicillin + clarithromycin) for the treatment of ...